A Phase 3 LBP To Treat Acute Graft-versus-Host-Disease

Savita Bernal, Chief Business Officer at MaaT Pharma, discussed the Phase 3 trial (ARES) in patients with acute Graft-versus-Host-Disease with gastrointestinal involvement.

Gastroenterology, Industry, Video

MaaT013 is currently being investigated in a pivotal Phase 3 trial (ARES) in patients with acute Graft-versus-Host-Disease with gastrointestinal involvement. ARES is the first Phase 3 trial globally for a microbiome-based therapy in hematooncology. MicroiomePost discussed this topic with Savita Bernal, Chief Business Officer at MaaT Pharma, during the Microbiome Connect: USA 2022 congress, held last November in Boston.

Staff editor

Most recent

Scientific research

HCPs Area

World Microbiome Day 2023: Microbes and Food

Probiotics for female indications: Impact of Probi® probiotics for bone health support

Industry

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

Read more about Gastroenterology, Industry, Video

Nutrition

A Phase 3 LBP To Treat Acute Graft-versus-Host-Disease

Most recent

Understanding the gut microbiota in athletes

Microbial signatures for food traceability: ensuring quality and safety from fermented wines to novel insect-based foods

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

HCPs Area

World Microbiome Day 2023: Microbes and Food

Probiotics for female indications: Impact of Probi® probiotics for bone health support

Industry

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

Microbial signatures for food traceability: ensuring quality and safety from fermented wines to novel insect-based foods

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

Microbiota linked to susceptibility to necrotizing enterocolitis in preemies

QIAGEN and McGill University partner to drive innovation in microbiome research

Dietary fiber, bloutia, and mucus function: uncovering potential for Next-Generation Probiotics

EnteroBiotix’s EBX-102 shows promising Phase 1b results for liver cirrhosis treatment

Dietary components may affect health differently based on gut microbiota